Estrella Immunopharma, Inc. (ESLA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
the bull case· 1
15
managers reporting positions in institutional filings
13fJun 30 '26the bear case· 2
1
managers whose positions make up most of the reported value
13fJun 30 '265 of 12
largest reporting managers cutting stakes in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Sep 24 '26 report. Not a forecast, not advice.
Estrella Immunopharma, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
tall tick = annual report · 1 on record
15 managers report a position worth $5.0M between them, and 1 of them hold 80% of it.
ESLA (Estrella Immunopharma, Inc.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
Estrella Immunopharma, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
High 0.55 at 10:15 am ET, low 0.51 at 2:00 pm ET.